The ongoing ASSAIL-MI trial has shown the potential for anti-IL-6 treatment to increase myocardial salvage in STEMI patients at the time of reperfusion [67], whilst previous evidence has highlighted the anti-arrhythmic potential of anti-IL-6R therapy in patients with rheumatoid arthritis and COVID-19 [53, 68]. The gene discussed is IL6R; the disease is rheumatoid arthritis.